Evidence map›Paper›PMID 25722303›Full record

ArticleMolecular cancer research : MCR2015

Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.

Uday Bhanu Maachani, Tamalee Kramp, Ryan Hanson, Shuping Zhao, Orieta Celiku, Uma Shankavaram, Riccardo Colombo, Natasha J Caplen, Kevin Camphausen, Anita Tandle

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Studies of Interaction Mechanism between Pyrido [3,4-Molecules (Basel, Switzerland) · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Uday Bhanu MaachaniRadiation Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Tamalee KrampRadiation Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Ryan HansonRadiation Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Shuping ZhaoRadiation Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Orieta CelikuRadiation Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Uma ShankavaramRadiation Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Riccardo ColomboNerviano Medical Sciences srl, Oncology, Nerviano, Italy.
Natasha J CaplenGenetics Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Kevin CamphausenRadiation Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Anita TandleRadiation Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland. tandlea@mail.nih.gov.
National Cancer Institute · US

Funding

The Synergy Between Radiotherapy and Molecularly Targeted AgentsZIASC010373 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI CAMPHAUSEN, KEVIN · 2009 to 2025
$22.2M
RNAi Analysis and Screening for Study of Genes and Anti-Cancer TreatmentsZIABC010939 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CAPLEN, NATASHA · 2009 to 2015
$3.1M
The Synergy Between Radiotherapy and Molecularly Targeted AgentsZ01SC010373 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI CAMPHAUSEN, KEVIN A · 2001 to 2008
$1.8M
Intramural NIH HHS Z01 SC010373Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

unlabelledTo ensure faithful chromosome segregation, cells use the spindle assembly checkpoint (SAC), which can be activated in aneuploid cancer cells. Targeting the components of SAC machinery required for the growth of aneuploid cells may offer a cancer cell-specific therapeutic approach. In this study, the effects of inhibiting Monopolar spindle 1, MPS1 (TTK), an essential SAC kinase, on the radiosensitization of glioblastoma (GBM) cells were analyzed. Clonogenic survival was used to determine the effects of the MPS1 inhibitor NMS-P715 on radiosensitivity in multiple model systems, including GBM cell lines, a normal astrocyte, and a normal fibroblast cell line. DNA double-strand breaks (DSB) were evaluated using γH2AX foci, and cell death was measured by mitotic catastrophe evaluation. Transcriptome analysis was performed via unbiased microarray expression profiling. Tumor xenografts grown from GBM cells were used in tumor growth delay studies. Inhibition of MPS1 activity resulted in reduced GBM cell proliferation. Furthermore, NMS-P715 enhanced the radiosensitivity of GBM cells by decreased repair of DSBs and induction of postradiation mitotic catastrophe. NMS-P715 in combination with fractionated doses of radiation significantly enhanced the tumor growth delay. Molecular profiling of MPS1-silenced GBM cells showed an altered expression of transcripts associated with DNA damage, repair, and replication, including the DNA-dependent protein kinase (PRKDC/DNAPK). Next, inhibition of MPS1 blocked two important DNA repair pathways. In conclusion, these results not only highlight a role for MPS1 kinase in DNA repair and as prognostic marker but also indicate it as a viable option in glioblastoma therapy. IMPLICATIONS: Inhibition of MPS1 kinase in combination with radiation represents a promising new approach for glioblastoma and for other cancer therapies.

Indexed as

AnimalsApoptosisBrain NeoplasmsCell Cycle ProteinsDNA RepairFemaleGlioblastomaHumansMice, NudeProtein Serine-Threonine KinasesProtein-Tyrosine KinasesRadiation ToleranceRandom AllocationTransfectionXenograft Model Antitumor AssaysCell Cycle ProteinsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesTTK protein, human

Identifiers

PMID25722303
PMCPMC4433451
OpenAlexW2108019002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.